GlassScriptPhysician profile
David Edward Bereda
NPI 1639319387
$3,590.56
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $598 · 2021: $1,620 · 2022: $822 · 2023: $119 · 2024: $57.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $176.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $612.43 | 2021-2024 | Qulipta |
| Novo Nordisk INC | $578.67 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $576.99 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $319.58 | 2020-2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $299.67 | 2021-2022 | |
| Allergan, INC. | $234.18 | 2020 | |
| Lilly USA, LLC | $217.56 | 2020-2022 | |
| Amgen INC. | $148.39 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.34 | 2019-2022 | |
| Dexcom, INC. | $69.90 | 2022-2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $54.52 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $51.19 | 2021 | |
| Glaxosmithkline, LLC. | $43.04 | 2021 | |
| Daiichi Sankyo INC. | $37.18 | 2022 | |
| Novartis Pharmaceuticals Corporation | $30.56 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.49 | 2021 | |
| Pfizer INC. | $29.52 | 2022-2023 | |
| Eisai INC. | $22.69 | 2021 | |
| Celgene Corporation | $19.83 | 2019 | |
| Organon LLC | $18.77 | 2023 | Nexplanon |
| Currax Pharmaceuticals LLC | $16.07 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.75 | 2021 | |
| Amarin Pharma, INC. | $15.17 | 2021 | |
| Astellas Pharma US INC | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bereda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.